Navigation Links
Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations
Date:1/27/2011

of the HeartMate II for DT and BTT in both North America and Europe, and we realized solid operating leverage as evidenced by our earnings growth,” he noted.

The company indicated that it ended 2010 with 254 HeartMate II centers globally, an increase of 43 centers during the year, with 211 centers worldwide now utilizing its new HeartMate peripherals, which are providing important quality of life benefits to patients and generating incremental revenue growth. In addition, there are now 90 centers with CMS (Centers for Medicare and Medicaid Services) certification for reimbursement for DT.

“As we begin 2011, we have a solid foundation upon which to build our business, and with our market development initiatives to drive referrals from cardiologists, facilitate center expansion, increase our international presence and realize continued improvements in patient outcomes, we are optimistic about our ability to achieve significant long-term growth,” Burbach commented.

“Additionally,” Burbach continued, “we have an active product pipeline that includes the continued evolution of the HeartMate II, the development of our next-generation pumps—HeartMate III, HeartMate X and PHP (Percutaneous Heart Pump)—and the introduction of cross-platform breakthrough technologies designed to enhance the HeartMate II, as well as future pump platforms. We believe these market-leading innovations will drive broader adoption of our offerings and enable us to serve an expanded patient population, while resulting in improved patient outcomes and quality of life, less invasive procedures and reduced cost of care,” he said.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $383.0 million in 2010 versus revenues of $280.0 million in 2009. The HeartMate product line accounted for $333.1 million in revenues, a 45 percent increase over sales of $229.8 million a year ago. The Thoratec® product line, which
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... 12 CVS Caremark Corporation (NYSE: CVS ) today announced ... of approximately 15%, to 8.75 cents per share on the Common ... record on January 22, 2010 . This increase translates into an annual ... per share from the previous rate of 30.5 cents . , ...
... , ST. JOSEPH, Mich. , Jan. 12 ... announced today they have been awarded a $336K Phase I ... for creating a novel type of predictive signatures for drug ... should overcome many shortcomings of existing methods of molecular diagnostics. ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2GeneGo Receives SBIR Grant 2GeneGo Receives SBIR Grant 3
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... TX (PRWEB) , ... July 01, 2015 , ... As ... another symptom found in a significant number of women: leg pain. Northeast Houston Vein ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Trevor L. Williams, ... South Florida and continued at USF earning a Master’s degree in Microbiology. He graduated ... member of the American Dental Association, the Florida Dental Association and the Academy of ...
(Date:7/1/2015)... ... 01, 2015 , ... Element Blue ™, a leading ... it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is ... multiple sources providing an environment where users can view and compare real-time and ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting ... a top ten list they hope will guide future mesothelioma research. Surviving Mesothelioma ... it now. , More than 450 mesothelioma patients, caregivers, and healthcare ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
... ... ... , , ... HARRISBURG, Pa. , ...
... ... ... ... ...
... alliance the Multilateral Initiative on Malaria (MIM), which advocates ... research environments in Africa. Malaria research has historically been ... has led to a huge gap in knowledge in ... in those areas where people are most affected by ...
... ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ... San Diego, CA (PRWEB) February ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ...
... ... has designated Houston Northwest Medical Center as a Blue Distinction Center for Spine Surgery. ... Houston, TX (Vocus) February 22, ... as a Blue Distinction Center for Spine Surgery. Blue Distinction Centers for Spine Surgery are ...
... ... ... ... ...
Cached Medicine News:Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 2Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 2Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 4Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 5Health News:Malaria research must be based in Africa 2Health News:Flexible Assembly Systems Announces New Torque Calculator App for the iPhone 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 2Health News:AppDynamics Announces General Availability of AppDynamics v2.0 3Health News:AppDynamics Announces General Availability of AppDynamics v2.0 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 5Health News:AppDynamics Announces General Availability of AppDynamics v2.0 6Health News:AppDynamics Announces General Availability of AppDynamics v2.0 7Health News:AppDynamics Announces General Availability of AppDynamics v2.0 8Health News:AppDynamics Announces General Availability of AppDynamics v2.0 9
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: